Introduction {#s1}
============

Cancer is a major public health burden all around the world which counts for one in 4 deaths in the United States [@pone.0074543-Siegel1]. The global burden of cancer continues to increase largely because of the aging and growth of the world population as well as an increasing adoption of cancer-related lifestyle, such as smoking, physical inactivity and ''westernized'' diets [@pone.0074543-Jemal1]. It was reported that there was about 12.7 million new cancer cases and 7.6 million cancer deaths throughout the world in 2008 [@pone.0074543-Ferlay1]. However, the mechanism of carcinogenesis is complicated and remains largely unknown. Many studies identified that genetics play a vital role in determining cancer risk and various genetic variations have been identified to elevate cancer risk [@pone.0074543-Risch1]. Single nucleotide polymorphisms (SNPs) are the most common form of human genetic variation and may contribute to individual's cancer risk through interaction with environmental factors [@pone.0074543-Lichtenstein1] `.`

Apoptosis plays an important role in various physiological functions and pathological processes, including immune diseases and carcinogenesis [@pone.0074543-Lowe1], [@pone.0074543-Evan1], and defects in apoptotic pathways are suggested to be associated with a number of human diseases, ranging from neurodegenerative disorders to various cancers [@pone.0074543-Thompson1]. FASL is a transmembrane protein belonging to the tumor necrosis factor (TNF) superfamily which can trigger apoptotic cell death by ligation to its receptor, Fas (CD95/APO-1). Numerous evidence suggested that FASL could mediate immune privilege in human tumors by inducing FAS-mediated apoptosis in tumor-specific lymphocytes [@pone.0074543-Randhawa1].

Recently many common low-penetrance genes have been considered as potential markers of cancer susceptibility. FASL gene is an important one of them, which situated on chromosome 1q23 with four exons. Though it is highly polymorphic, but the polymorphism C to T substitution at position -844(FASL-844C/T, rs763110) in the promoter region has been studied extensively [@pone.0074543-Takahashi1]. It is located in a binding motif for another transcription factor, CAAT/enhancer-binding proteinβand a higher basal expression of FASL is significantly associated with the FASL -844C allele compared with the - 844T allele [@pone.0074543-Wu1].

In the past decade, numerous studies have suggested that the FASL -844C/T polymorphism is associated with many types of cancers [@pone.0074543-Wang1]--[@pone.0074543-Liu2], but the results are conflicting rather than conclusive. Although two meta-analyses have discussed the rs763110 polymorphism and susceptibility to cancers [@pone.0074543-Liu3], [@pone.0074543-Zhang8], but they did not include all of the eligible studies, especially the case-control studies published in the past five years. Therefore, we performed this updated meta-analysis of 47 association studies of the FASL rs763110 polymorphism and cancer risk (including a total of 43,295 participates, approximately twice as many subjects as in previous such meta-analysis).

Methods {#s2}
=======

Publication search {#s2a}
------------------

PubMed and China National Knowledge Infrastructure (CNKI) were searched comprehensively using the terms relating to the FASL gene (e.g. "FASL", "FAS ligand" or "CD95L") in combination with words related to cancer (e.g. "cancer", "carcinoma", "tumor" or "neoplasm") and polymorphism or variation. Last search was updated on May 29, 2013.

In order to minimize potential publication bias, there were no language and other restrictions. Furthermore, citations in the retrieved articles were manually examined to identify additional relevant studies. Only the most recent or complete study was used if more than one of the same patient populations was applied in several publications.

Inclusion and exclusion criteria {#s2b}
--------------------------------

The major inclusion criteria were: (1) case-control or nested case-control studies; (2) investigating the association between the FASL rs763110 polymorphism and cancer risk; (3) cancers diagnosed by histopathology; (4) sufficient data for calculating an odds ratio (OR) with 95% confidence intervals (CIs). Accordingly, case-only studies, reviews and repeated papers were excluded.

Data extraction {#s2c}
---------------

Data were independently extracted by two reviewers (Xu and Zhou) and checked by the other authors. The following information was abstracted: name of the first author, year of publication, country where the study was conducted, genotyping method, ethnicity, cancer types, source of controls, age, gender, number of cases and controls, genotype frequency in cases and controls and Hardy-Winberg equilibrium (HWE). Different ethnicities were classified as Caucasian, Asian, and African. All eligible studies were defined as hospital-based (HB) or population-based (PB) according to the source of controls. In case of discrepancies, a consensus on each item was reached among the authors.

Statistical analysis {#s2d}
--------------------

For the controls of each study, Hardy-Winberg equilibrium (HWE) was evaluated using the goodness-of-fit chi-square test and a p\<0.05 was considered with a significant selective bias [@pone.0074543-Guo1]. Crude ORs with 95% CIs were used to assess the strength of association between the FALS rs763110 polymorphism and cancer susceptibility and a 95% CI without 1 for OR indicating a significantly increased or reduced cancer risk. The pooled ORs were performed for homozygote comparison (TT versus CC), heterozygote comparison (TC versus CC), dominant (TC+TT versus CC) and recessive (TT versus TC+CC) modes, respectively. Subgroup analyses were also performed to investigate the effects of confounding factors: cancer types, ethnicities, sample size (studies with more than 1000 subjects were sorted as "large", and studies with less than 1000 subjects were sorted as "small") and source of controls. Sensitivity analyses were conducted to identify individual study' effect on pooled results and test the reliability of results. Heterogeneity assumption was checked by the chi-square based Q test, and the heterogeneity was considered significant when p\<0.10 [@pone.0074543-Lau1]. The random-effects model (based on DerSimonian-Laird method) was used when heterogeneity existed among studies; otherwise the fixed-effects model (based on Mantel-Haenszel method) was applied [@pone.0074543-DerSimonian1]. Stratification and meta-regression analyses were used to detect the potential heterogeneity among studies. The presence of publication bias was examined by Begg's funnel plot and the Egger' linear regression test, and a p\<0.05 was considered significant [@pone.0074543-Egger1]. All statistical analyses were performed with STATA software (version 12.0; StataCorp, College Station, Texas USA). And all P values were two-side.

Results {#s3}
=======

Characteristics of eligible studies {#s3a}
-----------------------------------

After careful retrieve and selection, 44 articles (listed in [Table 1](#pone-0074543-t001){ref-type="table"}) were identified according to inclusion and exclusion criteria. The flow chart of selection was shown in [Figure 1](#pone-0074543-g001){ref-type="fig"}. Qureshi's and Chatterjee's studies sorted the data into three types of cancers and two ethnicities respectively. Each group in these studies was considered separately. Thus, a total of 47 case-control studies, including 19,810 cases and 23,485 controls were analyzed in this meta-analysis.

![PRISMA Flow Chart.\
\*a total of 44 articles were identified and five separate studies were reported in two articles, thus 47 studies were eligible](pone.0074543.g001){#pone-0074543-g001}
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###### Main characteristics of eligible studies.

![](pone.0074543.t001){#pone-0074543-t001-1}

  Author         Year     Country      Ethnicity    Cancer type     Study design     Method     Cases   Controls     Phwe
  ------------- ------ -------------- ----------- ---------------- -------------- ------------ ------- ---------- ----------
  Sun            2004      China         Asian       Esophageal          PB         PCR-RFLP     588      648       0.061
  Krippl         2004     Austria      Caucasian       Breast            PB          Taqman      489      487       0.418
  Lai            2005      China         Asian        Cervical           HB          Taqman      303      316       0.920
  Sun            2005      China         Asian        Cervical           PB         PCR-RFLP     314      615      0.002 \*
  Zhang          2005      China         Asian          Lung             PB         PCR-RFLP    1000      1270      0.180
  Yang           2005      China         Asian       colorectal          PB         PCR-RFLP     382      648       0.061
  Park           2006      Korea         Asian          Lung             HB         PCR-RFLP     582      582       0.570
  Li             2006      China         Asian        Bladder            HB         PCR-RFLP     216      252       0.234
  Zhang          2006       USA        Caucasian       SCCNH             HB         PCR-RFLP     721      1234      0.411
  Li             2006       USA        Caucasian      Melanoma           HB         PCR-RFLP     602      603       0.071
  Zhang          2007      China         Asian         Breast            PB         PCR-RFLP     839      830       0.110
  Erdogan        2007      Turkey      Caucasian      Thyroid            HB         PCR-RFLP     45       100       0.727
  Gormus         2007      Turkey      Caucasian      Ovarian            HB         PCR-RFLP     47        41       0.678
  Crew           2007       USA        Caucasian       Breast            PB          Taqman     1062      1105      0.602
  Ivansson       2007      Sweden      Caucasian      Cervical           PB          Taqman     1284      280       0.738
  Zhang          2007      Sweden      Caucasian      Melanoma           PB         PCR-RFLP     229      351       0.609
  Kang           2008      Korea         Asian        Cervical           HB         PCR-RFLP     154      160       0.327
  HSU            2008      China         Asian        Gastric            HB         PCR-RFLP     86       101       0.612
  Yang           2008      China         Asian       Pancreatic          PB         PCR-RFLP     397      907       0.986
  Ter-Minassi    2008       USA        Caucasian        Lung             HB          Taqman     2147      1490      0.254
  Chatterjee     2009   South Africa    African       Cervical           HB          Taqman      103      100       0.469
  Chatterjee     2009   South Africa    African       Cervical           HB          Taqman      327      315       0.457
  Wang           2009      China         Asian        Gastric            HB         PCR-RFLP     332      324       0.554
  Chen           2009      China         Asian       Esophageal          PB         PCR-RFLP     188      324       0.464
  Zhang          2010      China         Asian       Esophageal          HB         PCR-RFLP     204      248       0.254
  Zhou           2010      China         Asian        Cardiac            HB         PCR-RFLP     262      524       0.899
  Liu            2010      China         Asian        Cardiac            HB         PCR-RFLP     344      324       0.083
  Zhu            2010      China         Asian         Renal             HB          Taqman      353      365       0.278
  Kim            2010      Korea         Asian          AML              PB         PCR-RFLP     590      858       0.076
  Wang           2010      China         Asian          OSCC             PB         PCR-RFLP     294      333       0.271
  Cao            2010      China         Asian     Nasopharyngeal        PB         PCR-RFLP     563      610      0.004 \*
  Zhai           2010       USA        Caucasian     Esophageal          HB         PCR-RFLP     305      339       0.388
  Qureshi        2010       USA        Caucasian      Melanoma           PB         PCR-RFLP     217      852       0.427
  Qureshi        2010       USA        Caucasian        SCC              PB         PCR-RFLP     278      852       0.427
  Qureshi        2010       USA        Caucasian        BCC              PB         PCR-RFLP     286      852       0.427
  Zhang          2011      China         Asian        Gastric            HB         PCR-RFLP     234      321       0.094
  Shao           2011      China         Asian        Prostate           HB         PCR-RFLP     602      703       0.801
  Kupcinska s    2011     Germany      Caucasian      Gastric            HB          Taqman      114      238       0.715
  Mahfoudh       2012     Tunisia       African        Breast            PB         PCR-RFLP     438      332       0.334
  Tong           2012      China         Asian          ALL              HB         PCR-RFLP     361      519       0.137
  Wang           2012      China         Asian         Breast            HB         PCR-RFLP     420      496       0.112
  Zhang          2012      China         Asian        Cardiac            HB         PCR-RFLP     375      496       0.112
  Liu            2012      China         Asian        Gastric            HB         PCR-RFLP     218      218       0.073
  Li             2012      China         Asian        Ovarian            HB          ASMLDR      342      344       0.547
  Karimi         2012      India         Asian          OSCC            PB\*        PCR-RFLP     139      126       0.514
  Hashemi        2013       Iran         Asian         Breast            PB        T-ARMS-PCR    134      152       0.184
  Wang           2013      China         Asian         LHSCC             PB         PCR-RFLP     300      300       0.990

OSCC: oral squamous cell carcinoma; SCC: squamous cell carcinoma of skin; BCC: basal cell carcinoma of skin; SCCNH: squamous cell carcinoma of the head and neck; LHSCC: larynx and hypopharynx squamous cell carcinoma; ALL: acute lymphoblastic leukemia AML: acute myeloid leukemia PB: population-based; HB: hospital-based Phwe: Hardy-Winberg equilibrium; PB\*: not defined; Phwe\*\<0.05 ASMLDR: allele-specific multiple ligase detection reactions; T-ARMS-PCR: Tetra-amplification refractory mutation system--polymerase chain reaction; PCR-RFLP: Polymerase chain reaction-restriction fragment length polymorphism

Of the 47 studies, 42 were published in English and 5 in Chinese, 14 of them were studies of Caucasians, 30 studies of Asian and 3 studies of African (details shown in [Table 1](#pone-0074543-t001){ref-type="table"}). All cases were histopathologically confirmed. Controls were mainly matched for age and/or gender, of which 21 were population-based (PB) and 26 were hospital-based (HB). One of the studies did not show source of controls, we considered it to be population-based [@pone.0074543-Karimi1]. All studies showed that the distribution of genotypes in the control group was in agreement with the Hardy-Winberg equilibrium (HWE) except for two studies (Cao [@pone.0074543-Cao1], p = 0.004 and Sun [@pone.0074543-Sun1], p = 0.002).

Main results {#s3b}
------------

[Table 2](#pone-0074543-t002){ref-type="table"} showed the main results of this meta-analysis. Overall, significantly reduced cancer risk was associated with the FASL -844T allele when all studies were pooled (TC vs. CC: OR = 0.83, 95%CI = 0.75--0.92; P~heterogeneity~\<0.001, [Figure 2](#pone-0074543-g002){ref-type="fig"}; dominant model: OR = 0.85, 95%CI = 0.77--0.94; P~heterogeneity~\<0.001, [Figure 3](#pone-0074543-g003){ref-type="fig"}). No significant association was found in homozygote comparison (TT vs. CC: OR = 0.89, 95%CI =  0.79--1.01; P~heterogeneity~ = 0.074) or recessive model (TT vs. TC+CC: OR =  0.97, 95%CI =  0.86--1.09; P~heterogeneity~\<0.001).

![Subgroup analysis by ethnicity of ORs with a random-effects model for associations between the FASL rs763110 polymorphism and cancer risk under dominant model (TC+TT vs. CC).](pone.0074543.g002){#pone-0074543-g002}

![Subgroup analysis by cancer type of ORs with a random-effects model for associations between the FASL rs763110 polymorphism and cancer risk under heterozygote comparison (TC vs. CC).\
BC: breast cancer; LC: lung cancer; EC: esophageal cancer; CC: cervical cancer GC: gastric cancer & cardiac cancer AL: acute lymphoblastic leukemia & acute myeloid leukemia OC: ovarian cancer CHN: cancers of head and neck](pone.0074543.g003){#pone-0074543-g003}
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###### Meta-analysis results.

![](pone.0074543.t002){#pone-0074543-t002-2}

                       n         TT vs. CC           Ph           TC vs. CC           Ph          TT+TC vs. CC         Ph         TT vs. TC+CC        Ph
  ------------------- ---- ---------------------- --------- ---------------------- --------- ---------------------- --------- -------------------- ---------
  Total                47     0.89(0.79,1.01)       0.074     0.83(0.75,0.92)\*     \<0.001    0.85(0.77,0.94)\*     \<0.001    0.97(0.86,1.09)     \<0.001
  Cancer type                                                                                                                                      
  EC                   4     0.79(0.6,1.04)^a^      0.308       0.82(0.5,1.33)      \<0.001      0.82(0.52,1.3)      \<0.001   0.9(0.69,1.17)^a^     0.889
  LC                   3      0.84(0.58,1.23)       0.012      0.86(0.55,1.33)      \<0.001     0.85(0.56,1.31)      \<0.001   0.91(0.79,1.06)^a^    0.292
  BC                   6      0.85(0.62,1.16)       0.003      0.79(0.59,1.07)      \<0.001      0.82(0.61,1.1)      \<0.001    0.94(0.74,1.19)      0.029
  CC                   6     0.86(0.66,1.11)^a^     0.165      0.91(0.69,1.21)       0.013      0.90(0.67,1.21)      \<0.001   0.89(0.72,1.08)^a^    0.445
  Others               7       0.8(0.55,1.15)       0.003      0.83(0.67,1.02)       0.001      0.82(0.66,1.02)      \<0.001    0.87(0.63,1.20)      0.011
  Melanoma             3     1.22(0.93,1.59)^a^     0.277     1.11(0.94,1.32)^a^     0.968     1.13(0.96,1.33)^a^     0.803    1.15(0.89,1.49)^a^    0.272
  CHN                  6      0.94(0.66,1.33)       0.041    0.87(0.77,0.99)\*^a^    0.118    0.88(0.78,0.99)^\*a^    0.168      1.04(0.71,1.5)      0.008
  GC                   8       0.85(0.6,1.2)        0.038      0.73(0.53,1.01)      \<0.001     0.75(0.55,1.02)      \<0.001   0.94(0.76,1.15)^a^    0.234
  AL                   2      1.66(0.69,4.01)       0.001      0.91(0.57,1.45)       0.032     1.16(0.97,1.39)^a^     0.423     1.84(0.57,5.95)     \<0.001
  OC                   2    0.48(0.27,0.87)\*^a^    0.547    0.67(0.49,0.9)\*^a^     0.187    0.64(0.48,0.86)\*^a^    0.199    0.65(0.38,1.11)^a^    0.744
  Source of control                                                                                                                                
  PB                   21       0.84(0.7,1)        \<0.001    0.82(0.72,0.93)\*     \<0.001    0.83(0.73,0.95)\*     \<0.001    0.92(0.79,1.07)     \<0.001
  HB                   26     0.95(0.80,1.13)      \<0.001    0.84(0.73,0.97)\*     \<0.001    0.87(0.76,0.99)\*     \<0.001    0.97(0.86,1.09)     \<0.001
  Ethnicity                                                                                                                                        
  Asian                30     0.83(0.68,1.02)      \<0.001    0.76(0.67,0.87)\*     \<0.001     0.79(0.7,0.9)\*      \<0.001    0.95(0.77,1.16)     \<0.001
  Caucasian            14    0.98(0.89,1.09)^a^     0.182     1.03(0.96,1.1)^a^      0.518     1.02(0.95,1.09)^a^     0.399    0.96(0.88,1.06)^a^    0.335
  African              3     0.88(0.64,1.2)^a^      0.595     0.84(0.62,1.13)^a^     0.290     0.85(0.64,1.12)^a^     0.396    0.95(0.78,1.17)^a^    0.700
  Sample size                                                                                                                                      
  Large                17     0.88(0.75,1.02)      \<0.001    0.86(0.76,0.98)\*     \<0.001    0.86(0.76,0.98)\*     \<0.001    0.93(0.83,1.04)      0.043
  Small                30     0.91(0.74,1.11)      \<0.001     0.81(0.7,0.93)\*     \<0.001    0.84(0.73,0.97)\*     \<0.001    0.99(0.813,1.21)    \<0.001
  Genotyping method                                                                                                                                
  PCR-RFLP             36     0.86(0.74,1.01)      \<0.001    0.79(0.70,0.87)\*     \<0.001    0.80(0.72,0.90)\*     \<0.001    0.98(0.84,1.15)     \<0.001
  Taqman               9     0.98(0.86,1.11)^a^     0.855     1.08(0.99,1.18)^a^     0.801     1.05(0.97,1.14)^a^     0.803    0.93(0.83,1.03)^a^    0.855

N: number of studies included; OR: odds ratio; Ph: p value for heterogeneity; BC: breast cancer; LC: lung cancer; EC: esophageal cancer; CC: cervical cancer GC: gastric cancer & cardiac cancer AL: acute lymphoblastic leukemia & acute myeloid leukemia OC: ovarian cancer CHN: cancers of head and neck PB: population-based; HB: hospital-based; \*OR with statistical significance; large: studies with more than 1000 participants; small: studies with less than 1000 participants; PCR-RFLP: Polymerase chain reaction-restriction fragment length polymorphism; ^a^OR: estimates for fixed effects model.

In the sub-group analyses by ethnicity, significant reduced risks were found for T carriers among Asians (TC vs. CC: OR = 0.76, 95%CI = 0.67--0.87; P~heterogeneity~\<0.001, [Figure 2](#pone-0074543-g002){ref-type="fig"}; dominant model: OR = 0.79, 95%CI = 0.70--0.90; P~heterogeneity~\<0.001). In Caucasians and Africans, however, no significant association was found in each comparison.

When we performed sub-group analyses by cancer types, reduced cancer risk was found in the heterozygote and dominant model comparison for cancers of head and neck ( TC vs. CC: OR = 0.87, 95%CI = 0.77--0.99; P~heterogeneity~ = 0.118; dominant model: OR = 0.88, 95%CI = 0.78--0.99; P~heterogeneity~ = 0.168, [Figure 3](#pone-0074543-g003){ref-type="fig"}) and ovarian cancer (TC vs. CC: OR = 0.67, 95%CI = 0.49--0.90; P~heterogeneity~ = 0.187; TT+TC vs. CC: OR = 0.64, 95%CI = 0.48--0.86; P~heterogeneity~ = 0.199, [Figure 3](#pone-0074543-g003){ref-type="fig"}), respectively.

The results of the sub-group analyses by sample size, source of control and genotyping method were shown in supplemental information (Figure S1 -- S3 in [File S1](#pone.0074543.s002){ref-type="supplementary-material"}). We found a statistically significant link between the FASL rs763110 polymorphism and cancer risk in studies utilizing genotyping method with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in heterozygote and dominant model comparison (TC vs. CC: OR = 0.79, 95%CI = 0.70--0.87; P~heterogeneity~\<0.001; dominant model: OR = 0.80, 95%CI = 0.72--0.90; P~heterogeneity~\<0.001), but not for studies using Taqman assay.

Heterogeneity {#s3c}
-------------

Heterogeneity among studies was identified in overall comparisons and also in sub-group analyses (shown in [Table 2](#pone-0074543-t002){ref-type="table"}). To examine the potential source of heterogeneity, meta-regression was performed using variables as cancer type, source of control, ethnicity, genotyping method and sample size in heterozygote comparison (TC vs. CC). The results revealed that ethnicity (p = 0.029) and genotyping method (p = 0.043) but not cancer types (p = 0.772), sample size (p = 0.518), or source of controls (p = 0.826) contributed to the source of heterogeneity.

Sensitivity analysis {#s3d}
--------------------

Leave-one-out sensitivity analysis was performed to explore individual study's influence on the pooled results. The results revealed that no individual study affected the pooled OR significantly since no substantial change was found (figure not shown).

Publication bias {#s3e}
----------------

Begg's funnel plot and Egger's test were performed to assess the publication bias. The figure of the funnel plot did not show any evidence of obvious asymmetry (p = 0.430 for TC vs. CC) ([Figure 4](#pone-0074543-g004){ref-type="fig"}). Then, the Egger's test was used to statistical test and publication bias was not detected either (p = 0.572 for TT vs. CC, p = 0.714 for TC vs. CC, p =  0.967 for dominant model, and p = 0.388 for recessive model, respectively).

![Funnel plot of heterozygote comparison (TC vs. CC).\
Funnel plot of all 47 eligible studies p =  0.430, Egger's test p = 0.02; the circles represent the weight of individual study.](pone.0074543.g004){#pone-0074543-g004}

Discussion {#s4}
==========

A total of 47 eligible studies, including 19,810 cases and 23,485 controls were identified and analyzed in this meta-analysis. We demonstrated that the FASL -844T allele was associated with a statistically reduced risk of cancer. This significant association was found in Asians but not for Caucasians or Africans. With all published data, this finding might be plausible.

All controls in the studies involved were mainly cancer-free. The distribution of genotype in the control group was consistent with the Hardy-Weinberg equilibrium in all studies except for two studies (shown in [Table 1](#pone-0074543-t001){ref-type="table"}). When excluding these two studies, the pooled OR and heterogeneity were not significantly changed indicating that the control group could represent the base population.

The FAS/FASL signaling system plays an important role in the cell apoptosis pathway, including regulation of immune system, maintaining immune-privileged ability and performing other regulatory functions [@pone.0074543-Los1], [@pone.0074543-Rashedi1]. FAS is a cell surface receptor which expresses in various tissues [@pone.0074543-Los2], and FASL is the natural ligand to FAS [@pone.0074543-VillaMorales1]. The FAS combination with the FASL may trigger the death signal cascade, and subsequently leads cells to die. It has been reported that the aberration of expression of FAS and/or FASL results in cancer cells resisting the killing of T lymphocytes and is related to many human tumors [@pone.0074543-Lin1], [@pone.0074543-Wu2]. SNPs in a gene may influence its transcription or translation and eventually alter the biological function. The most popular polymorphism for FASL is a C to T changes at nucleotide position -844(rs763110) in the promoter region which may influence FASL expression, apoptosis signaling pathway, and ultimately contribute to the susceptibility to cancer. Numerous researches have proved that the FASL rs763110 polymorphism was associated with cancer risk (studies listed in [Table 1](#pone-0074543-t001){ref-type="table"}). However, the results were controversial. Although meta-analyses of this polymorphism have been performed by the former scholars, in our present study, much more data were included and may get more comprehensive information.

With newly added studies, we carried out sub-group analyses. When stratified by ethnics, we found a significant association in Asians, but not for Caucasians or Africans, which may suggest that ethnic variation of genetic background would be modified by environmental factors [@pone.0074543-Hirschhorn1], such as age, sex, diet, lifestyle, smoking, BMI, and so on. In our study, the frequency of the FASL-844T alleles was 28.4%, 36.9%, and 62.8% in Asians, Caucasians, and Africans respectively, and the -844 C to T mutant rate among them maybe different, which may count for the results stratified by ethnics. Furthermore, it was reported that studies with small size may have insufficient statistical power to investigate a slight effect on the pooled results or may produce a fluctuated risk estimate, which may cause the ethnic differences [@pone.0074543-Wacholder1]. We could find that the participants of the three ethnicities differ greatly from each other in [Table 2](#pone-0074543-t002){ref-type="table"}.

In the sub-group analysis by cancer type, no significant association was found except for heterozygote and dominant model comparison of ovarian cancer and cancers of head and neck (shown in [Table 2](#pone-0074543-t002){ref-type="table"}). In our study, the cancers of head and neck subgroup consisted of cancers of oral cavity, pharynx and larynx, thyroid, and nasopharynx, and most of them were squamous cell carcinoma. Gastman and colleagues reported that the FAS/FASL pathway may participate in the immunosuppression process in head and neck cancer [@pone.0074543-Gastman1]. Based on our findings, we speculate that the -844C/T rs763110 polymorphism of FASL may be a potential genetic biomarker for risk of head and neck cancer. As for the significance of ovarian cancer, the relatively small sample size may weaken the statistical power and lead to the results considerable, so many case-control studies with more participants investigating ovarian cancer and the -844C/T rs763110 polymorphism are needed to prove the result. Different cancer risks were also found in the studies using different genotyping methods. We discovered that the association was significant among studies utilizing PCR-RFLP assay, but not for studies with Taqman genotyping assay. This may be explained that most studies for Asians utilizing PCR-RFLP, nevertheless Taqman was the main genotyping method for Caucasian and African studies.

Attention should be paid to the relatively large heterogeneity in our results. Meta-regression was performed for heterozygote model according to ethnicity, cancer type, source of control, genotyping method and sample size. We found the sources of heterogeneity were mainly from ethnicity (p = 0.029) and genotyping method (p = 0.043). In addition, through sub-group analysis by ethnicity, we found that I-squared for the Asian, Caucasian and African studies was 80.9%, 0.0% and 19.3%, respectively ([Figure 2](#pone-0074543-g002){ref-type="fig"}). Then we demonstrated that the heterogeneity might mainly come from the Asian studies. In fact, many other factors may also be the potential source of heterogeneity. Due to lack of detailed data, we had to give up performing a meta-regression utilizing these variables.

Some limitation should be noted in this meta-analysis. Firstly, the controls were not uniformly defined and some studies included inpatient with benign disease which may contribute to the FASL gene mutation and development of various cancers. Secondly, due to limited individual data, we did not conduct a more precise analysis on other covariates such as age, gender, and environmental factors. Thirdly, the heterogeneity is difficult to exclude, in that it is influenced by complicated factors, such as age, sex, genetic diversities, different lifestyle, and clinical characteristics.

Despite these limitations, our meta-analysis had significantly higher statistical power than the previous study that analyzed the association between the FASL -844C/T rs763110 polymorphism and cancer risk, since the cancer patients involved in our meta-analysis were twice as many as the previous one. We also analyzed the rs763110 polymorphism in various populations, including Africans. Cancer types in our study were more multifarious and a significant association was also found in cancers of head and neck and ovarian cancer though the sample size was relatively small.

In conclusion, this meta-analysis suggests that the FASL-844C/T rs763110 polymorphism is associated with a significantly reduced risk of cancer, especially in Asian populations. To verify these results, large scale case-control studies with detailed individual information are needed.
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